Frontiers in Pharmacology · 6 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes literature on CD10 (neprilysin), a cell-surface metalloprotease implicated in cardiovascular, oncologic, neurodegenerative, metabolic, and pain-related conditions, along with the current state of CD10 inhibitor development. The review finds that despite broad preclinical interest, clinical studies of CD10 inhibitors remain exceedingly rare and no successful drugs have reached the marketplace.
This narrative review compiles existing literature on CD10, a zinc-dependent ectoenzyme also known as neprilysin, covering its physicochemical properties, tissue expression, molecular functions, disease associations, and inhibitor development. CD10 is described as a biomarker for hematopoietic and tissue stem cells with roles in cardiovascular regulation, immune function, pain signaling, oncogenesis, aging, and Alzheimer's disease pathogenesis. The authors summarize evidence linking CD10 to leukemia, solid tumors, heart failure, obesity, type-2 diabetes, complex regional pain syndrome, osteoarthritis, and COVID-19. They note that CD10 inhibitors have shown therapeutic promise in preclinical contexts but emphasize that clinical studies are exceedingly rare and molecular mechanisms remain unclear, with no successful CD10-targeted drugs having reached the marketplace.
